Literature DB >> 10609658

A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis.

J B Zuckerman1, C B Robinson, K S McCoy, R Shell, T J Sferra, N Chirmule, S A Magosin, K J Propert, E C Brown-Parr, J V Hughes, J Tazelaar, C Baker, M J Goldman, J M Wilson.   

Abstract

A third-generation adenoviral vector containing recombinant human cystic fibrosis transmembrane conductance regulator (CFTR) gene was delivered by bronchoscope in escalating doses to the conducting airway of 11 volunteers with cystic fibrosis. Assessments of dose-limiting toxicity (DLT), efficiency of gene transfer, and cell-mediated and humoral immune responses to vector administration were performed. DLT, manifest by flulike symptoms and transient radiographic infiltrates, was seen at 2.1 x 10(11) total viral particles. A highly specific assay for gene transfer was developed using in situ hybridization with an oligoprobe against unique vector sequence. Detectable gene transfer was observed in harvested bronchial epithelial cells (<1%) 4 days after vector instillation, which diminished to undetectable levels by day 43. Adenovirus-specific cell-mediated T cells were induced in most subjects, although only mild increases in systemic humoral immune response were observed. These results demonstrate that gene transfer to epithelium of the lower respiratory tract can be achieved in humans with adenoviral vectors but that efficiency is low and of short duration in the native CF airway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10609658     DOI: 10.1089/10430349950016384

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  34 in total

Review 1.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

2.  The challenge of using gene- or cell-based therapies to treat lung disease.

Authors:  Ronald G Crystal
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

3.  Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance.

Authors:  Salvatore Alesci; Shiromi M Perera; Edwin W Lai; Christina Kukura; Mones Abu-Asab; Maria Tsokos; John C Morris; Karel Pacak
Journal:  Endocrinology       Date:  2007-05-24       Impact factor: 4.736

4.  A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Authors:  David A Hokey; Robert Wachholder; Patricia A Darrah; Diane L Bolton; Dan H Barouch; Krystal Hill; Veerabadran Dheenadhayalan; Stephan Schwander; C Steven Godin; Macaya Douoguih; Maria Grazia Pau; Robert A Seder; Mario Roederer; Jerald C Sadoff; Donata Sizemore
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

6.  Genetic diseases, immunology, viruses, and gene therapy.

Authors:  James M Wilson
Journal:  Hum Gene Ther       Date:  2014-04       Impact factor: 5.695

7.  Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Authors:  B G Harvey; P L Leopold; N R Hackett; T M Grasso; P M Williams; A L Tucker; R J Kaner; B Ferris; I Gonda; T D Sweeney; R Ramalingam; I Kovesdi; S Shak; R G Crystal
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 8.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

9.  "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.

Authors:  M A Croyle; N Chirmule; Y Zhang; J M Wilson
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 10.  Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose.

Authors:  D T Klink; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.